Licencing Opportunity:
This work represents a licensing opportunity.
LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via up-regulation of VHL in a colon cancer cell line.
Biochemical pharmacology 2010 Jun 23; In press
Lee K, Kang J JE, Park S SK, Jin Y, Chung K KS, Kim H HM, Lee K, Kang M MR, Lee M MK, Song K KB, Yang E EG, Lee J JJ, Won M
Dongguk University-Seoul, Seoul, 100-715; Molecular Cancer Research Center, KRIBB, Ochang 363-883.
Hypoxia inducible factor HIF-1 is responsible for radiation resistance and poor prognosis in cancer therapy. As part of our drug discovery program, a novel HIF inhibitor, LW6, was identified as a small compound that inhibits the accumulation of HIF-1alpha. We found that LW6 decreased HIF-1alpha protein expression without affecting HIF-1beta expression. MG132, a proteasome inhibitor, protected HIF-1alpha from LW6-induced proteasomal degradation, indicating that LW6 affects the stability of the HIF-1alpha protein. We found that LW6 promoted the degradation of wild type HIF-1alpha, but not of a DM-HIF-1alpha with modifications of P402A and P564A, at hydroxylation sites in the oxygen-dependent degradation domain (ODDD). LW6 did not affect the activity of prolyl hydroxylase (PHD), but induced the expression of von Hippel-Lindau (VHL), which interacts with prolyl-hydroxylated HIF-1alpha for proteasomal degradation. In the presence of LW6, knockdown of VHL did not abolish HIF-1alpha protein accumulation, indicating that LW6 degraded HIF-1alpha via regulation of VHL expression. In mice carrying xenografts of human colon cancer HCT116 cells, LW6 demonstrated strong anti-tumor efficacy in vivo and caused a decrease in HIF-1alpha expression in frozen-tissue immunohistochemical staining. These data suggest that LW6 may be valuable in the development of a HIF-1alpha inhibitor for cancer treatment.